Lithium interferes with reserpine-induced dopamine depletion.
Long-term lithium treatment attenuated the hypokinetic effect of reserpine in a patient with tardive dyskinesia. In rats, prophylactic lithium administration inhibits reserpine-induced dopamine depletion in the brain. These data indicate that lithium may limit the therapeutic efficacy of reserpine in tardive dyskinesia.
D000328:Adult; D000818:Animals; D001714:Bipolar Disorder / Q000188:drug therapy; D003342:Corpus Striatum / Q000378:metabolism; D004298:Dopamine / Q000378:metabolism; D018492:Dopamine Antagonists; D004409:Dyskinesia, Drug-Induced / Q000188:drug therapy*; D006220:Haloperidol / Q000009:adverse effects; D006801:Humans; D008094:Lithium / Q000009:adverse effects* / Q000627:therapeutic use; D016651:Lithium Carbonate; D008297:Male; D009714:Nucleus Accumbens / Q000378:metabolism; D010640:Phenothiazines / Q000009:adverse effects; D051381:Rats; D011919:Rats, Inbred Strains; D011954:Receptors, Dopamine / Q000378:metabolism; D012110:Reserpine / Q000037:antagonists & inhibitors* / Q000627:therapeutic use
D018492:Dopamine Antagonists; D010640:Phenothiazines; D011954:Receptors, Dopamine; D016651:Lithium Carbonate; D012110:Reserpine; D008094:Lithium; D006220:Haloperidol; D004298:Dopamine